Context Therapeutics (CNTX) Capital Expenditures (2022 - 2026)

Context Therapeutics has reported Capital Expenditures for 5 years, with the latest figure at $37258.0 in Q1 2026.

• Quarterly Capital Expenditures rose 9.75% year-over-year to $37258.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $37258.0 (down 9.71% YoY) and the FY2025 annual result came in at $33948.0, up 364.02% from the prior year.
• Capital Expenditures climbed to $37258.0 in Q1 2026 per CNTX's latest filing, from $33948.0 in the prior quarter.
• Over five years, Capital Expenditures peaked at $37258.0 in Q1 2026 and troughed at -$24000.0 in Q3 2023.
• A 5-year average of $12817.6 and a median of $7316.0 in 2024 frame the typical range for Capital Expenditures.
• The sharpest annual moves came in 2023 and 2024: Capital Expenditures tumbled 219.11% in 2023, then jumped 130.48% in 2024.
• Over 5 years, Capital Expenditures stood at $1837.0 in 2022, then soared by 1682.8% to $32750.0 in 2023, then plunged by 77.66% to $7316.0 in 2024, then surged by 364.02% to $33948.0 in 2025, then grew by 9.75% to $37258.0 in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $37258.0, $33948.0, and $7316.0 for Q1 2026, Q1 2025, and Q3 2024 respectively.